Abstract Number: 3662

Systems-based Care Improvements to Optimize BTK Inhibitors in Chronic Lymphocytic Leukemia Vary in the Community Setting








INTRODUCTION

The management of chronic lymphocytic leukemia (CLL) has evolved considerably, including recent approvals of targeted therapies that significantly expand the treatment landscape and improve patient outcomes. As more drugs and combinations join the therapeutic armamentarium, it is increasingly urgent to understand the evidence for each and select the right drug for the right patient. However, too many patients do not receive proper testing to guide therapy and large



numbers receive inappropriate chemotherapy even after testing. To resolve real-world barriers to the integration of guideline- and evidence-based care, a 4-phase, implementation-science, systems-based initiative was developed.

METHODOLOGY




teams/systems

Phase 3

Plan-Do-Study-Act (PDSA) Follow-Up


Partners

Advocacy groups: CLL Society, The Leukemia & Lymphoma Society **Education:** PlatformQ Health and Global Education Group



Interventions

The initiative was submitted and approved by a centralized institutional review board.



Phase 4 **Network Dissemination of Findings**



PREMIER

Authors: Tariqa Ackbarali, PhD, MS, CHCP¹; Danielle M. Brander, MD²; Matthew S. Davids, MD, MMSc³ Affiliation: ¹PlatformQ Health Education, Needham, MA; ²Duke University, Durham, NC; ³Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

Data Collection:


RESULTS



Patient Charts




Team Member Surveys



Patient Surveys

Molecular Testing





		_
	C	ÐO
٦		ÐO
	Ē	ดิด
		- 45


Patient Chart Demographics

Category	Patient	Percentage
Gender	Male	67 %
Age	70-79 years	76 %
Race/Ethnicity	White/non-Hispanic	99 %
Insurance	Medicare	54 [%]
		n=141

Chart Review Summary:

Measure	Baseline n=141	Follow-u n=75
Molecular Testing/FISH		
IGHV mutation reported	28 %	61 %
Not reported/ordered	13 %	7%
Chromosomal Abnormalities Reported		
Abnormalities present	65 %	86%
No abnormalities present	35%	35%
First-line Treatment		
Targeted therapy [BTKi vs BCL2]	46 [%] vs 7 [%]	52% vs 4
Chemotherapy [BR vs FCR]	18% vs 12%	19 [%] vs 7
Second-line Treatment	n=71	n=41
Targeted therapy [BTKi vs BCL2]	49% vs 10%	54 [%] vs 2
Chemotherapy [BR vs FCR]	10 [%] vs 1 [%]	5% vs 0
Third-line Treatment	n=30	n=17
Targeted therapy [BTKi vs BCL2]	53 [%] vs 10 [%]	47% vs 2
Fourth-line Treatment	n=13	n=12
Targeted therapy [BTKi vs BCL2]	39 [%] vs 31 [%]	58 [%] vs2
Fifth-line Treatment	n=11	n=6
Targeted therapy [BTKi vs BCL2]	18 [%] vs 45 [%]	50 [%] vs 3
Evidence of:	n=141	n=75
Shared decision-making	85%	100%
Assessment of side effects	57%	83%
Counseling on cardio toxicities	50%	71%
Consultation with cardiology	34%	49 %
Patient education and counseling		
Patient-education materials	50 %	61 %
Face-to-face counseling	34%	96 %

This initiative was supported by an independent educational grant from AstraZeneca Pharmaceuticals.



This systems-based initiative resulted in meaningful advancements in practice, set new standards for testing and patient-centered care, and provided educational resources for community-based teams. Action-plan domains provide solution-oriented guidance for other community-based practitioners and teams for ease of implementing best practices in the wider hematology/oncology community. The educational initiative and overall impact continue to be evaluated through the course of all 4 phases.

N/A



Utilization of Targeted Therapy

Chart Data

of charts showed targeted therapy use (monotherapy or combination)

Survey data - Team

of team members reported using targeted therapy as their preferred choice

Survey data - Patient



Center 2 [ID]

6mo 9mo

83% 100%

0% 100% 100% 0% 100% 100%

of patients said they received targeted therapy for their CLL

Center 3 [NC]

3mo 6mo 9mo

N/A

30% 100% 100%

50% 75% 90%

50% 50% 100%

education]
the nurses do a
typical teach.
We call it a
'chemo-teach' but
it's for whatever
treatment that
they're receiving."

"[For patient

"A patient had disease progression and began new treatment with acalabrutinib in July 2023."

"RNs will now teach for infusion education and document the encounter. Specialty pharmacy will educate on oral oncolytics."

"At the Oncology Leadership Meeting in March 2024, our hospital system decided to participate in a hospital-wide smoking cessation QI project for the whole hospital system, not just for oncology. As of July 2024, we will begin implementing a new documentation process for smoking cessation that providers and MOAs will utilize."

"Centralized hematopathology lab re-engaged post site-webinar and adopted reflex testing as standard, impacting 4 additional centers."